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Evaluation and Management of the Cardiac Amyloidosis
Joseph B. Selvanayagam, FRACP, DPHIL,*‡ Philip N. Hawkins, PHD, FRCP, FRCPATH,†
Biju Paul, MBBS,‡ Saul G. Myerson, MD, MRCP,* Stefan Neubauer, MD, FRCP*
Oxford and London, United Kingdom; and Adelaide, Australia
Cardiac amyloidosis describes clinically significant involvement of the heart by amyloid deposition, which may or
may not be associated with involvement of other organs. The purpose of this review is to summarize the current
state of evidence for the effective evaluation and management of cardiac amyloidosis. Acquired systemic amy-
loidosis occurs in more than 10 per million person-years in the U.S. population. Although no single noninvasive
test or abnormality is pathognomonic of cardiac amyloid, case-control studies indicate that echocardiographic
evidence of left ventricular wall thickening, biatrial enlargement, and increased echogenicity in conjunction with
reduced electrocardiographic voltages is strongly suggestive of cardiac amyloidosis. Furthermore, newer echo-
cardiographic techniques such as strain and strain rate imaging can demonstrate impairment in longitudinal
function before ejection fraction becomes abnormal. Recent observational studies also suggest that cardiovascu-
lar magnetic resonance imaging yields characteristic findings in amyloidosis, offering promise for the early de-
tection of cardiac involvement, and the presence of detectable cardiac troponin and elevated B-type natriuretic
peptide in serum of affected patients portends an adverse prognosis. Management strategies for cardiac amy-
loid are largely based on nonrandomized single-center studies. One of the few published randomized studies
shows the superiority of oral prednisolone and melphalan compared with colchicine in systemic AL amyloidosis.
Intermediate-dose infusional chemotherapy regimes (such as vincristine, adriamycin, and dexamethasone) and
high-dose chemotherapy with peripheral stem cell rescue have been used widely, but treatment-related mortality
remains substantial with chemotherapy. Recent studies also indicate promising strategies to stabilize the native
structures of amyloidogenic proteins; inhibit fibril formation; and disrupt established deposits using antibodies,
synthetic peptides, and small-molecule drugs. (J Am Coll Cardiol 2007;50:2101–10) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.028s
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Cmyloidosis is a clinical disorder caused by extracellular
eposition of insoluble abnormal fibrils, derived from ag-
regation of misfolded normally soluble protein (1,2).
bout 20 different unrelated proteins, which share a patho-
nomonic ultrastructure, are known to form amyloid fibrils
n vivo (3). Systemic amyloidosis, in which amyloid deposits
re present in the viscera, blood vessel walls, and connective
issues, is usually fatal and is the cause of about 1 per 1,000
eaths in developed countries. There are also various local-
zed forms of amyloidosis in which the deposits are confined
o specific foci or to a particular organ or tissue. “Cardiac
myloidosis” is used here to describe involvement of the
eart by amyloid deposition, whether as part of systemic
myloidosis (as is most commonly the case) or as a localized
henomenon.
rom the *Department of Cardiovascular Medicine, University of Oxford, John
adcliffe Hospital, Oxford, United Kingdom; †National Amyloidosis Centre, De-
artment of Medicine, Royal Free and University College Medical School, London,
nited Kingdom; and the ‡Department of Cardiovascular Medicine, Flinders
edical Centre, Adelaide, Australia.m
Manuscript received January 3, 2007; revised manuscript received August 27, 2007,
ccepted August 28, 2007.Variation in nomenclature, and the fact that there are
everal types of amyloid, each with its unique features and
reatment, can result in underdiagnosis and errors in patient
anagement. The purpose of this review is to summarize
he current state of evidence for the effective clinical
valuation and management of cardiac amyloidosis.
vidence Acquisition
e performed a systematic review of peer-reviewed publi-
ations that were identified through searches of MEDLINE
nd the Cochrane Database from 1980 to June 2007.
esides cardiac amyloidosis and plasma cell dyscrasia, we
earched all drugs used to treat plasma cell dyscrasia.
eywords were used alone and with the modifiers of
iagnosis, treatment, clinical effects, troponin, electrocardiogra-
hy, echocardiography, and magnetic resonance imaging. Bib-
iographies from these references were reviewed, as were
dditional articles identified by content experts. Criteria
sed for study selection included study design, English
anguage, relevance to clinicians, and validity based on
enue of publication.
lassification. Acquired systemic amyloidosis occurs in
ore than 10 per million person-years in the U.S. popula-
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Cardiac Amyloidosis November 27, 2007:2101–10tion (4), is the cause of death in
about 1 in 1,000 of the British
population, and is probably
much underdiagnosed in the el-
derly population. Systemic AL
amyloidosis is the most serious
and commonly diagnosed form,
with 2,000 to 2,500 new cases
annually in the U.S. (5).
Systemic AA amyloidosis. For-
merly known as secondary amy-
loidosis, systemic AA amyloid-
osis is a complication of chronic
inflammatory conditions, or in-
deed, any disorder associated
with a sustained acute-phase re-
sponse in which there is mark-
dly increased production of serum amyloid A protein
SAA). Renal disease dominates the clinical picture in AA
myloidosis, and the condition almost always presents with
roteinuria and renal failure. Regression of AA amyloid
ollowing suppression of SAA production may lead to
eversal of organ dysfunction (6). Clinically significant
nvolvement of the heart is very rare (7).
ystemic AL amyloidosis. Previously known as primary
myloidosis, systemic AL amyloidosis is the most com-
only diagnosed form of clinical amyloid disease in devel-
ped countries. The AL fibrils are derived from monoclonal
mmunoglobulin light chains and consist of the whole or
art of the variable (VL) domain. Almost any B-cell
yscrasia, including myeloma, lymphomas, and macro-
lobulinaemia, may be complicated by AL amyloidosis, but
ore than 80% of cases are associated with subtle and
therwise “benign” monoclonal gammopathies. Multiorgan
nfiltration is typical. It occurs equally in men and women,
sually over the age of 50 years but as early as the third
ecade. The heart is affected pathologically in up to 90% of
L patients, in 50% of whom diastolic heart failure with
hysical signs of right heart failure is a presenting feature.
onversely,5% of patients with AL amyloidosis involving
he heart have clinically isolated cardiac disease (8). Clinical
valuation of suspected cardiac AL amyloid includes screen-
ng for syncope (9), dizziness, postural hypotension, easy
ruising (10), painful sensory polyneuropathy (10% to 20%
f patients), and carpal tunnel syndrome (20%) (11), as well
s major visceral involvement of the liver and kidneys. The
resence of both periorbital purpura and macroglossia has
ow sensitivity (10% to 20%) but is highly specific for the
resence of disease (12). Death in more than one-half of
hese patients is due either to heart failure or arrhythmia.
Hereditary systemic amyloidosis is caused by deposition of
myloid fibrils derived from genetic variants of transthyretin
TTR) (13), apolipoprotein A-I, lysozyme (14), or fibrino-
en alpha-chain and other extremely rare variants. Clinical
yndromes include cardiomyopathy, nephropathy, or neu-
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
imaging
ECG  electrocardiogram/
electrocardiographic
LV  left ventricular
SAA  serum amyloid A
protein
SAP  serum amyloid P
component
SSA  senile systemic
amyloidosis
TTR  transthyretinopathy (15), though the heart is most prominently involved tn variant TTR type, which is associated with more than
00 different TTR mutations, most often with associated
europathy. This entity is not rare; indeed, the amyloido-
enic TTR Val122Ile variant is present in 4% of African
mericans, and 23% of African Americans with cardiac
myloidosis have this variant (16).
Senile systemic amyloidosis (SSA) is caused by deposition of
myloid fibrils derived from normal wild-type transthyretin
nd almost always presents as a slowly progressive, infiltra-
ive amyloid cardiomyopathy. Senile systemic amyloidosis is
xceptionally rare in those younger than 60 years of age, but
ts prevalence ranges from 25% to 36% in those older than
0 years of age (17,18). There is a large male predominance,
nd senile systemic amyloidosis has a major predilection
or the heart (19,20). Patients usually present with conges-
ive heart failure, with carpal tunnel syndrome being the
nly common accompanying extracardiac manifestation.
ormal-voltage electrocardiogram (ECG) with a left ante-
ior fascicular block and thickened left ventricular (LV)
alls on echocardiography are characteristic. Despite the
lder age and greater myocardial infiltration, the median
SA survival of 75 months is greater than for AL amyloid-
sis (21). The slowly progressive nature, despite greater
yocardial infiltration, distinguishes SSA from AL amy-
oidosis. Diagnosis is often surmised but can be achieved
efinitively by the demonstration of TTR type amyloid on
ither cardiac or, occasionally, other (e.g., rectal) biopsy,
long with absence of mutations in the TTR gene. There
s no specific therapy available, and death is usually due to
ongestive heart failure or arrhythmias.
oninvasive Evaluation of Cardiac Amyloidosis
chocardiography can show several features that are sug-
estive of cardiac amyloidosis (Fig. 1), though the classical
eatures are commonly present only in the later stages of
isease (22,23), and there is a wide spectrum of echocar-
iographic findings. Echocardiography cannot confrim di-
gnosis in isolation, and the images should be interpreted in
he context of the clinical picture and other investigations.
he AA amyloid very rarely affects the heart, and the
ommon types that do, such as AL and variant/wild-type
TR types, cannot be distinguished by echocardiogram
lone. Although very rare indeed, hereditary apolipopro-
ein A-I amyloidosis sometimes involves the heart, produc-
ng similar echocardiographic abnormalities.
The most common echocardiographic feature is thicken-
ng of the LV wall, particularly in the absence of hyperten-
ion. (22,24–28) This is often referred to incorrectly as
hypertrophy” because the pathological process is infiltra-
ion, not myocyte hypertrophy. This feature has poor
pecificity for amyloidosis because of its occurrence with
ther conditions, such as hypertensive heart disease, hyper-
rophic cardiomyopathy, and other infiltrative cardiac dis-
ases (glycogen storage diseases, sarcoidosis, hemochroma-
osis). The combination of increased LV mass in the
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November 27, 2007:2101–10 Cardiac Amyloidosisbsence of high ECG voltages may be more specific for
nfiltrative diseases, of which amyloid is the most common
24,29). High sensitivity (72% to 79%) and specificity (91%
o 100%) have been reported for this combination (27,29),
hough some study sizes are small and may be influenced by
eferral bias. The Dubrey et al. study (8) did not include a
omparison group but showed low ECG voltages in 70% to
4% of amyloid patients with mildly increased LV wall
hickness (1.1 cm).
Increased echogenicity of the myocardium, particularly
ith a granular or “sparkling” appearance, has been reported
n several studies (10,27,28,30,31). This can occur in other
auses of LV hypertrophy, however (10,27,30), and al-
hough high specificity rates are quoted (71% to 81%)
10,27), the populations studied were those referred with
uspected amyloid, and this specificity may not be reflective
f real-life practice. Moreover, sensitivity tends to be low,
ith this pattern seen in 26% to 36% of cardiac amyloid
ases (27,32–34), apart from a single study suggesting a
ensitivity of 87% (10). It should be noted that this granular
attern applies only to standard echocardiographic imaging,
ithout tissue harmonics being applied, as this increases
yocardial echogenicity in general. Newer echocardio-
raphic image processing techniques may also reduce the
ranular appearance. Thus, although increased echogenicity
s common in amyloid, its usefulness as a discriminating
actor is limited.
Reduced systolic function, as measured by low ejection
raction or poor wall thickening, is uncommon until the
Figure 1 2D Echocardiographic Image (Parasternal Long-Axis
View) From a Patient With AL Cardiac Amyloidosis
Two-dimensional (2D) echocardiographic image (parasternal long-axis view)
from a patient with AL cardiac amyloidosis showing normal biventricular dimen-
sions, granular “sparkling” ventricular wall appearance, concentric left ventricu-
lar wall thickening, and thickened mitral valve leaflets suggesting infiltration. Ao
 aorta; IVS  interventricular septum; LA  left atrium; LV  left ventricle;
RV  right ventricle.ore severe stages of disease and can be absent in up to 75% if cases (12,23,25–27,33). Diastolic dysfunction is the hall-
ark, and may be present in all patients, though its
dentification can be difficult with standard techniques, with
1% to 88% of patients showing a restrictive pattern on
oppler mitral inflow assessment (25,35,36). The variable
revalence of diastolic dysfunction may also be related to the
everity of disease in the group studied, as the likelihood of
restrictive physiological pattern increases with the severity
f disease (25,36). Tissue Doppler imaging has shown
educed diastolic velocities in both early and late cardiac
myloid (22,37), so even early diastolic dysfunction could be
dentified (when wall thickening is minimal), though dis-
inguishing individuals with and without heart failure is
ore difficult, with significant overlap between the groups
37). It is, however, good at distinguishing amyloid and
ther restrictive cardiomyopathies from constrictive pericar-
itis, with a mitral annular diastolic velocity (E=) 8 cm/s a
ood discriminator for restrictive physiology (38). Fi-
ally, although diastolic dysfunction is commonly (if not
niformly) present, it should be remembered that dia-
tolic dysfunction is not specific for amyloidosis and
hould be taken together with the clinical picture and
ther investigations.
Other features of cardiac amyloid include thickened
alves and a small pericardial effusion, and although these
ave been described in 40% to 60% of patients (28,33), they
end to be present in more advanced disease (12). Again, it
hould be remembered that these are highly selected groups
n the studies. Similarly, bilaterally enlarged atria have been
escribed in 27% to 50% (27,28,33) but are not specific for
myloid (27). A thickened interatrial septum has been
hown in a minority of patients (28), and a study by Falk
t al. (30) showed it to be specific for amyloid in the later
tages of the disease, with 100% specificity. This was in a
elatively small group of patients, however, and has not been
eproduced subsequently. Other parameters such as atrial
train and ventricular strain rate imaging show mean
ifferences between amyloid groups with and without
eart failure (38,39), but the considerable overlap in
alues between groups limits the clinical application of
hese techniques.
In summary, there are many echocardiographic features
ommon in amyloid, though none are highly specific indi-
idually, and a combination of several is helpful in achieving
diagnosis. An echocardiogram demonstrating marked LV
all thickening, biatrial enlargement, thickened valve leaf-
ets, and a pericardial effusion in the context of reduced
CG voltages is highly persuasive of cardiac amyloid. If
ither a thickened interatrial septum or a granular highly
chogenic myocardium is also present, this makes the
iagnosis even more likely (30). Combining features has
een shown to be good at differentiating cardiac amyloid
rom other diagnoses (40,41), though the most useful
ethod is to combine these with the wider clinical findings.
lectrocardiography. Systematic study of ECG findingsn biopsy-confirmed cardiac amyloidosis is relatively sparse.
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Cardiac Amyloidosis November 27, 2007:2101–10urtagh et al. (42) from the Mayo Clinic provide the
argest report to date of ECG findings in a population of
atients with AL amyloidosis and biopsy-proven cardiac
nvolvement. In 127 patients, they found that low ECG
oltage (presence of QRS voltage amplitude 0.5 mV in all
imb leads or 1 mV in all precordial leads) (Fig. 2) was
resent in 46% of patients, and a pseudo-infarct pattern
i.e., no infarct actually evident on echocardiography) was
resent in 47% of patients. The pseudo-infarct patterns
ere anterior (36%), inferior (12%), and lateral (14%). Both
ow ECG voltage and pseudo-infarct pattern were present
n 25% of patients. There was a moderate correlation
etween the presence of low voltage and pericardial effusion
ut no correlation between voltage and the ejection fraction.
trial fibrillation and flutter was the most common arrhyth-
ia. It was present in 25% of patients with LV hypertrophy,
hereas 7% of patients without LV hypertrophy were
dentified as having atrial fibrillation (42). None of the
lectrocardiographic variables correlated with survival.
hough low voltage and pseudo-infarct patterns are com-
on, increased voltages suggesting LV hypertrophy are
ccasionally found in amyloid. These findings are similar to
n earlier report in 196 patients (with high clinical suspicion
f cardiac amyloid) by Rahman et al. (27), who noted low
CG voltage in 56% and pseudo-infarct pattern in 60% of
atients who were subsequently confirmed to have cardiac
myloid. In multivariate logistic regression analysis, a com-
ination of a low voltage and measures of myocardial
hickness produced the best discriminator of cardiac in-
olvement in this study. The investigators found that if low
oltage was present on ECG and interventricular septal
hickness was1.98 cm on echocardiography, the diagnosis
f cardiac amyloidosis could be made with a sensitivity of
2% and a specificity of 91%. In this model, the positive
redictive and negative predictive values were 79% and 88%
espectively, although the findings may not be applicable in
Figure 2 Typical Appearance of the Electrocardiogram in Cardi
There is low voltage with lateral T-wave inversion and poor R-wave progression in the general population given the selective nature of the
ohort study (27).
Signal-averaged ECG is often abnormal (delayed myo-
ardial activation or “late potentials”) in patients with AL
myloidosis. Dubrey et al. (43) found that late potentials
ere more frequent in patients with echocardiographic
vidence of cardiac amyloidosis (31%) compared with pa-
ients with normal echocardiograms (9%, p  0.003) (43).
urthermore, abnormal signal-averaged electrocardiograms
ere also independently predictive of sudden death in the
ubgroup of patients with an abnormal echocardiogram
p  0.05). Reduced heart rate variability on 24-h ECG
onitoring has been found to predict short-term mortality
n both AA and AL amyloidosis in a small case series (44)
nd probably represents autonomic dysfunction.
ardiovascular magnetic resonance imaging (CMR). A
trength of CMR using late gadolinium enhancement
echnique is the ability to “phenotype” various forms of
ardiomyopathy with high spatial resolution and reproduc-
bility (45,46). Maceira et al. (47) studied 29 patients with
ystemic amyloidosis and 16 hypertensive controls using
adolinium-enhanced CMR. Amyloidosis was associated
ith qualitative global and subendocardial gadolinium
nhancement of the myocardium (Fig. 3). Subendocardial
ongitudinal relaxation time (T1) in amyloid patients was
horter than in control subjects and was correlated with
arkers of increased myocardial amyloid load, such as LV
ass, wall thickness, interatrial septal thickness, and dia-
tolic function. Global subendocardial late gadolinium en-
ancement was found in approximately two-thirds of pa-
ients. On the basis of pathological correlates in a patient
rom this study, the CMR hyperenhancement probably
epresents interstitial expansion from amyloid infiltration.
Perugini et al. (48) studied an Italian population of
atients with histologically proven systemic amyloidosis and
chocardiographic diagnosis of cardiac involvement. Gado-
yloidosis
cordial leads.ac Am
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November 27, 2007:2101–10 Cardiac Amyloidosisinium enhancement by CMR was detected in 16 of 21
76%) patients. In contrast to the study of Maciera et al.
47), where the pattern of late enhancement was global and
ubendocardial, Perugini et al. (48) reported a much more
ariable pattern of late enhancement, that could be localized
r diffuse, and subendocardial or transmural. Transmural
xtension of hyperenhancement (i.e., how much of the LV
all thickness was enhanced) within each patient signifi-
antly correlated with LV end systolic volume. The number
f enhanced segments correlated with LV end-diastolic
olume, end-systolic volume, and left atrial size. An espe-
ially unique feature of delayed-enhancement magnetic
esonance imaging appearances in this population is the
lood pool’s atypically dark appearance, which reflects the
imilar myocardial and blood T1 values attributable to high
yocardial uptake and fast blood pool washout. Although it
s yet to be proved, imaging with a highly reproducible and
uantifiable technique such as CMR may help to estimate
he prevalence of cardiac involvement in systemic amyloid-
sis when cardiac morphological changes are not apparent
y echocardiography. Screening of subclinical early cardiac
nvolvement may become possible should delayed enhance-
ent prove to have adequate sensitivity in detecting amyloid
nfiltration. Improved noninvasive surveillance may also aid
n the evaluation of new chemotherapeutic agents.
adiolabeled serum amyloid P component (SAP) scin-
igraphy. Serum amyloid P component is a highly con-
erved, invariant plasma glycoprotein of the pentraxin family
hat becomes specifically and highly concentrated in amy-
oid deposits of all types as a result of its calcium-dependent
Figure 3 End-Diastolic Frames of Cines
Horizontal long-axis (A) and short-axis (B) at the mid-ventricular level, showing
pleural (*) and pericardial effusions (**) and asymmetrical hypertrophy (maxi-
mal end-diastolic wall thickness: septum 22 mm, lateral wall 9 mm, wall thick-
ness ratio of 2.6). Corresponding images using the delayed-enhancement
magnetic resonance imaging technique: C and D, respectively. The horizontal
long-axis image demonstrates global subendocardial hyperenhancement of
both ventricles, both atria and the interatrial septum. The short-axis image
displays a ring of subendocardial hyperenhancement (arrows).inding to all types of amyloid fibril. Following intravenous Lnjection, radiolabeled SAP distributes between the circu-
ating and the amyloid-bound SAP pools in proportion to
heir size and can then be imaged and quantified (49,50).
his safe noninvasive method provides unique information
n the diagnosis, distribution, and extent of amyloid depos-
ts throughout the body, and serial scans monitor progress
nd response to therapy. Serial SAP scans have unequivo-
ally demonstrated that amyloid deposits of all types regress
n a proportion of patients when the supply of the respective
myloid fibril precursor protein is sufficiently reduced.
nfortunately, planar SAP scintigraphy is unable to image
myloid in the moving heart.
iochemistry. Cardiac biomarkers are elevated in cardiac
L amyloidosis, often to a degree that seems to be dispro-
ortionate to symptoms of congestive heart failure (51).
hat cardiac troponins are detected is not surprising, as
roponin values are invariably associated with pathological
vidence of cardiac injury, irrespective of causation (52,53).
yonecrosis and small-vessel ischemia due to amyloid deposit
ead to an increase in cardiac troponins (54), whereas diastolic
ysfunction and increased genetic expression of natriuretic
eptide genes in the amyloid infiltrated ventricles lead to an
ncrease in plasma B-type natriuretic peptide (BNP) levels
55). Troponin T and I and N-terminal (NT)-proBNP
evels at diagnosis provide prognostic information in amy-
oidosis. In the largest series to date, Dispenzieri et al. (56)
ound that in 261 newly diagnosed patients with cardiac
myloidosis, detectable cardiac troponin I or T conferred a
edian survival of 6 or 8 months (respectively), compared
ith 22 or 21 months (respectively) in those without any
etectable troponin I/T. Furthermore, their data imply that
aised values of serum cardiac troponins may surpass symp-
omatic congestive heart failure and 2-dimensional echocar-
iography as predictors for survival.
The role of cardiac biomarkers in monitoring disease
rogression or response to therapy is still being defined.
uriously, in AL amyloidosis, NT-proBNP values can fall
apidly following effective chemotherapy; a 30% reduction
n NT-proBNP levels after 3 doses of chemotherapy has
een associated with improved event-free survival, though
his did not correlate with objective assessments on the
chocardiogram (57). Prognosis with a hematological re-
ponse following chemotherapy is substantially better than
n patients without, and the basis for changes and the true
alue of serial NT-proBNP measurements in the manage-
ent of AL amyloidosis are not yet clear.
A new serum immunoglobulin free light chains assay, which
an quantify the aberrant circulating amyloidogenic fibril pro-
ein precursor with great sensitivity in 85% to 98% of patients
ith AL amyloidosis, is a major recent advance in the disease
57). This automated immunoassay can serially monitor pro-
uction of amyloidogenic light chains during chemotherapy
58). A 50% reduction in aberrant serum free light chains
ollowing chemotherapy was paralleled by reductions in NT-
roBNP and associated with improvement clinically but not in
V wall thickness (57). Further imaging studies with a highly
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Cardiac Amyloidosis November 27, 2007:2101–10eproducible and quantifiable technique such as CMR may
elp to define correlations between cardiac function and
hanges in free light chains.
anagement of Cardiac Amyloidosis
he twin aims of management in systemic amyloidosis are:
) reduction in the supply of amyloid fibril precursor
roteins to decrease new amyloid formation and perhaps
acilitate the natural regression of existing deposits; and 2)
crupulous general supportive care, including dialysis and
rgan transplantation in some cases (Fig. 4). Management
nd prognosis differ substantially in different types of
myloidosis, and accurate fibril typing, frequently including
eoxyribonucleic acid analysis, is a prerequisite to optimal
are. Unfortunately, the prognosis of cardiac amyloidosis is
ften very poor at diagnosis, especially in patients with AL
ype, in whom there may also be significant extracardiac
nvolvement. Awareness of the compromised functional
Figure 4 Flow Diagram Outlining the Evaluation of a Patient W
BNP  B-type natriuretic peptide; CMR  cardiovascular magnetic resonance; DNA
ECG  electrocardiogram; LV  left ventricle; SAP  serum amyloid P componenteserve of amyloidotic organs and extreme care to protect
enal function are critically important.
eneral supportive care. The restrictive cardiac physiol-
gy and autonomic neuropathy differentiate treatment of
HF in patients with amyloid. The mainstay of the
reatment of heart failure in AL amyloidosis is the use of
iuretics, with high doses being required in some patients
ith nephrotic syndrome. Meticulous attention to fluid
alance is essential, with daily weights and patient-
ontrolled adjustment of diuretic dose often being helpful.
here are no data on the use of beta-blockers in patients
ith cardiac amyloidosis (59). The restrictive cardiac filling
nd autonomic neuropathy may lead to severe bradycardia
nd hypotension, thus limiting their use. Vasoactive drugs,
ncluding angiotensin-converting enzyme inhibitors and
ngiotensin II inhibitors, should be used with caution in
ardiac amyloidosis because even small doses may cause
rofound hypotension. In addition, both digoxin and cer-
ain calcium blockers bind to amyloid fibrils, and this
spected Cardiac Amyloidosis
oxyribonucleic acid;
transthyretin.ith Su
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November 27, 2007:2101–10 Cardiac Amyloidosisnteraction may account for the increased susceptibility to
igoxin toxicity and to hemodynamic deterioration with
alcium blockers (60,61). Despite widespread vascular fra-
ility seen in this condition, anticoagulation should not be
ithheld when cardiac thrombus has been demonstrated
ithin the heart, in atrial fibrillation or when there is sinus
hythm with failure of atrial contraction (62,63).
All manner of arrhythmias have been described in cardiac
myloidosis; the most common of those causing symptoms
s atrial fibrillation (64). Although sudden death is frequent
n amyloidosis (65), very little is known about the terminal
lectrical events, and potential benefit of prophylactic anti-
rrhythmic therapy has been little studied. In our limited
xperience, electromechanical dissociation is not infrequent.
he indications for pacing in cardiac amyloidosis are essen-
ially similar to those in general practice, though concurrent
utonomic neuropathy and hypoalbuminemia can substan-
ially exacerbate hypotension-associated poor cardiac out-
ut. The threshold for introducing pacing is therefore often
ower in patients with amyloidosis, and the restrictive
ature of their hemodynamic dysfunction may respond
articularly well to dual-chamber systems that can opti-
ize the atrial filling component. Implantable cardiac
efibrillators have been used only in a small number of
ases. These have not yet been shown to prolong survival,
nd death is usually due to electromechanical dissociation
r congestive heart failure (66). One patient with amyloid
ardiomyopathy received a continuous intra-axial cardiac
ow pump in the feasibility of long-term continuous axial
ow pump study (67). Left ventricular support devices
ave not been systematically evaluated in patients with
ardiac amyloidosis.
anagement of underlying amyloid disease process. Ra-
ional management of the disorders underlying amyloid
eposition has been improved greatly by recent availability
f routine assays for the circulating amyloid fibril precursor
roteins SAA in AA amyloidosis, and serum immunoglob-
lin free light chains in AL amyloidosis (as described
arlier). Treatment of the underlying inflammatory disorder
n AA amyloidosis that reduces the SAA concentration
oward healthy values dramatically improves survival (6).
he new biological agents that inhibit tumor necrosis factor
nd interleukin-1 potently suppress the acute-phase re-
ponse in many patients with rheumatoid arthritis, seroneg-
tive spondyloarthropathies, Crohn’s disease, and some
ereditary periodic fever syndromes (68). Treatment with
olchicine largely prevents AA amyloidosis in familial Med-
terranean fever (69). Excision of solitary Castleman’s dis-
ase masses that secrete interleukin-6 can be every effective
hen this condition is complicated by AA amyloidosis (70).
Chemotherapy targeting clonal plasma cells that produce
he monoclonal amyloidogenic immunoglobulin light
hains can arrest amyloid formation and lead to regression
f deposits, preservation of organ function, and enhanced
urvival in many patients with systemic AL amyloidosis
71,72). Availability of a robust, sensitive immunoassay for 7mmunoglobulin-free light chains in serum has been one of
he most important advances in management of AL amy-
oidosis. The AL fibril precursor protein can now be
onitored prospectively and chemotherapy tailored accord-
ngly in most cases. Sustained reduction of the serum
oncentration of the aberrant monoclonal light chain value
y 50% or more is associated with enhanced survival (72).
nfortunately, many patients with AL amyloidosis tolerate
hemotherapy poorly, and a proportion of plasma cell clones
re refractory even to high-dose therapy. Oral melphalan
nd prednisolone are tolerated better than more aggressive
reatment, but responses are few and much delayed (73).
ntermediate-dose infusional chemotherapy regimes, such
s vincristine, adriamycin, and dexamethasone, or melpha-
an and dexamethasone, which can also be given orally, can
nduce swifter responses. High-dose chemotherapy coupled
ith peripheral autologous stem cell rescue (often referred
o as stem cell transplantation) has lately been used quite
idely, but treatment-related mortality in this setting is 10%
o 25%, especially outside specialist amyloidosis centers
23,71). The presence of cardiac amyloidosis is a major
eterminant of increased morbidity and mortality from
eripheral stem cell transplantation (74,75). Cardiac amy-
oidosis reflects reduced peri-transplant survival compared
o those without cardiac involvement. Presence of conges-
ive heart failure, syncope, arrhythmias, renal failure, poor
unctional status, and involvement of 2 visceral organs
redicts a poor outcome and should be excluded for stem
ell transplant therapy (75,76). Cardiac involvement, an
ssential part of screening for stem cell transplantation, may
e underestimated by echocardiography. Other approaches
urrently being explored include thalidomide/lenolidamide
lone or in combination chemotherapy (77), rituximab in
atients with CD20-positive clones, and new agents
ncluding the proteasome inhibitor bortezomib, although
o reports exist as to the efficacy of the latter 2 agents.
dequate responses to less intense chemotherapy indicate
hat high-dose regimes may be excessive, but there is
resently no way to identify which individuals will
olerate and respond best to which treatment. The key
bjective is to sufficiently suppress production of the
myloidogenic free light chain without unacceptable
oxicity, and this requires careful individual assessment
nd monitoring. Interestingly, recent studies using serial
easurements of NT-proBNP during chemotherapy sug-
est that cardiac function in AL can improve rapidly in
ome cases in association with reduction of the circulating
myloidogenic precursor, despite the amount of cardiac
myloid deposits remaining apparently unaltered on echo-
ardiography (57).
At present, apart from transplantation to replace failed
rgans and liver transplantation to remove the source of
myloidogenic proteins of hepatic origin, only symptomatic
reatment is available in hereditary systemic amyloidosis.
he liver is the main source of plasma TTR, and more than
00 liver transplants have been performed in hereditary
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Cardiac Amyloidosis November 27, 2007:2101–10TR amyloidosis since this “surgical gene therapy” ap-
roach was introduced in 1991. Outcome is generally good
n younger, fitter patients carrying the common Met30
myloidogenic mutation, but paradoxical acceleration of
ransthyretin amyloid deposition can occur in the heart
ollowing liver transplantation in older patients with non-
et30 variants (78). A few combined heart and liver
ransplants have been performed, which so far appear to
ircumvent this predicament.
The livers removed from patients with hereditary TTR
myloidosis contain only microscopic amyloid deposits in
he blood vessels and interstitial tissues and retain normal
unction. A large number of “domino” liver transplants
ave therefore been conducted in recipients with various
erminal liver diseases for whom normal donor livers were
ot available. This has certainly prolonged their lives, but
he first such recipient has now developed symptomatic
ystemic TTR amyloidosis just 8 years after transplanta-
ion (79).
ardiac transplantation. Heart transplantation for cardiac
myloidosis has been performed relatively rarely because of
oncern about progression of amyloid in other organs and
he possibility of amyloid deposition in the donor heart.
wenty-four cases have been performed in the United
ingdom (80). Seventeen patients had AL amyloidosis and
had non-AL forms of amyloidosis. Survival of the 10 AL
atients who had no adjunctive chemotherapy was 50% at 1
ear and 20% at 5 years; amyloid recurred in the grafts of
hese patients after a median of 11 months, and extracardiac
myloid deposition contributed to mortality in 70% of the
atients. Survival of 7 patients with AL who also had
hemotherapy was 71% and 36% at 1 and 5 years, with 2
atients alive at 10 years. Survival of the 7 patients with
on-AL was 86% and 64% at 1 and 5 years. One such
atient with hereditary apoAI amyloidosis had recurrence of
myloid in the graft at 60 months on routine post-transplant
iopsies but has no functional deficit after 13 years. Five-
ear survival for all 24 amyloid patients was 38%, compared
ith 67% among patients (n  4,058) undergoing cardiac
ransplantation in the United Kingdom for other indica-
ions. Recently, sequential heart and stem cell transplant has
hown promise in younger patients complicated with car-
iac failure but with preserved renal, gastrointestinal, and
utonomic function (81,82). Seventeen patients have been
reated with this aggressive approach. Using extended car-
iac donor criteria, transplants were performed within 2
onths of diagnosis. Induction followed by standard triple-
herapy cardiac immunosuppression was continued
hroughout stem cell transplant. Myeloablative high-dose
elphalan was followed by stem cell infusion 6 months after
ecovery. Sequential transplant patients had a significant
urvival advantage. Survival at 1 year was 80% versus 17%
or nontransplant patients. This was associated with the
bsence of relapse of plasma cell dyscrasias and allograft
ejection. Though the ethical dilemma of offering cardiac transplant to patients with systemic amyloidosis exists,
equential heart and stem cell transplant offers a feasible
trategy for patients with systemic amyloidosis complicated
y heart failure.
ovel therapies. Elucidation of aspects of the molecular
athogenesis of amyloidosis has generated a variety of novel
pproaches to therapy. We have developed a drug that
argets SAP with the goal of eliminating SAP from amyloid
eposits in the hope that this may reduce amyloid deposi-
ion and/or accelerate amyloid clearance (83). Preliminary
pen-label studies are in progress to study safety and
olerability and optimize dosing. Double-blind controlled
linical trials in AA amyloidosis with eprodisate, a small
olecule glycosaminoglycan aimed at blocking the pro-
myloidogenic interaction between SAA and glycosamino-
lycans, have just been completed. Promising early findings
ave lately been released (84) for renal disease in AA
myloidosis, further studies on the use of this drug as an
djuvant in AL amyloidosis are warranted, and detailed
nalysis of outcomes is awaited. Small-molecule ligands that
tabilize the native tetrameric structure of TTR and prevent
ts fibrillogenesis are being actively investigated for prophy-
axis and therapy in TTR amyloidosis. Further strategies
nclude stabilizing the native structures of other amyloido-
enic proteins and disrupting established deposits using
ntibodies, synthetic peptides, and small-molecule drugs.
ome of these potential new therapies will enter clinical
rials within the next few years and offer exciting prospects
or improvements in treatment.
onclusions
ardiac amyloidosis describes clinically significant involve-
ent of the heart by amyloid deposition, which may or may
ot be associated with involvement of other organs. Al-
hough no single noninvasive test abnormality is pathogno-
onic of cardiac amyloid, a combination of a typical
chocardiographic appearance and low-voltage ECG com-
lexes is highly suggestive of disease. New imaging tech-
iques such as CMR may offer promise for the early
etection of cardiac involvement. In AL amyloidosis, che-
otherapy may arrest and even reverse the disease, with
esultant stabilization or improvement of symptoms. Thus,
arly diagnosis is critical because patients with advanced
isease are usually too ill for intensive chemotherapy.
ardiac biomarkers, troponin T and I, and NT-proBNP are
ensitive markers of cardiac involvement and prognostic
eterminants. The recent introduction of immunoglobulin
ight-chain assay is a sensitive marker of response to therapy
nd survival in AL amyloidosis. Recognition of non-AL
ardiac amyloidosis is vital in avoiding unnecessary chemo-
herapy; to screen family members; and potentially, in the
ear future, to provide new medications that will stabilize
he amyloidogenic protein.
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